Teva Pharmaceutical Industries Research and Development Expenses 2010-2024 | TEVA

Teva Pharmaceutical Industries annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Teva Pharmaceutical Industries research and development expenses for the quarter ending September 30, 2024 were $0.240B, a 5.14% decline year-over-year.
  • Teva Pharmaceutical Industries research and development expenses for the twelve months ending September 30, 2024 were $977M, a 4.27% increase year-over-year.
  • Teva Pharmaceutical Industries annual research and development expenses for 2023 were $0.953B, a 13.72% increase from 2022.
  • Teva Pharmaceutical Industries annual research and development expenses for 2022 were $0.838B, a 13.34% decline from 2021.
  • Teva Pharmaceutical Industries annual research and development expenses for 2021 were $0.967B, a 3.01% decline from 2020.
Teva Pharmaceutical Industries Annual Research and Development Expenses
(Millions of US $)
2023 $953
2022 $838
2021 $967
2020 $997
2019 $1,010
2018 $1,213
2017 $1,778
2016 $2,111
2015 $1,525
2014 $1,488
2013 $1,427
2012 $1,356
2011 $1,095
2010 $951
2009 $825
Teva Pharmaceutical Industries Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30 $240
2024-06-30 $269
2024-03-31 $242
2023-12-31 $226
2023-09-30 $253
2023-06-30 $240
2023-03-31 $234
2022-12-31 $210
2022-09-30 $175
2022-06-30 $228
2022-03-31 $225
2021-12-31 $243
2021-09-30 $222
2021-06-30 $248
2021-03-31 $254
2020-12-31 $293
2020-09-30 $258
2020-06-30 $225
2020-03-31 $221
2019-12-31 $233
2019-09-30 $240
2019-06-30 $276
2019-03-31 $261
2018-12-31 $295
2018-09-30 $311
2018-06-30 $290
2018-03-31 $317
2017-12-31 $346
2017-09-30 $531
2017-06-30 $469
2017-03-31 $432
2016-12-31 $684
2016-09-30 $663
2016-06-30 $375
2016-03-31 $389
2015-12-31 $446
2015-09-30 $361
2015-06-30 $386
2015-03-31 $332
2014-12-31 $379
2014-09-30 $412
2014-06-30 $344
2014-03-31 $353
2013-12-31 $411
2013-09-30 $348
2013-06-30 $339
2013-03-31 $329
2012-12-31 $442
2012-09-30 $324
2012-06-30 $298
2012-03-31 $292
2011-12-31 $371
2011-09-30 $242
2011-06-30 $243
2011-03-31 $239
2010-12-31 $288
2010-09-30 $239
2010-06-30 $222
2010-03-31 $211
2009-12-31 $219
2009-09-30 $195
2009-06-30 $169
2009-03-31 $219
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.384B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00